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Abstract 
Background: There are many benefits of maintaining healthy blood glucose levels, and studies have shown that 
lifestyle changes such as changes to diet can successfully restore normoglycaemia in participants with dysglycaemia. 
Significant health-related lifestyle changes are often difficult to implement and functional ingredients that can reduce 
glycaemic and insulaemic responses may help at risk populations. The aim of this study was to investigate whether a 
mulberry leaf extract could lower the glycaemic and insulinaemic responses to 75 g sucrose in healthy individuals.
Methods: A double-blind, randomised, placebo-controlled, crossover design trial was conducted by the Oxford 
Brookes Centre for Nutrition and Health. Thirty-eight participants were recruited into the trial and, after an overnight 
fast, were given 75 g sucrose + white mulberry leaf extract, or 75 g sucrose alone. Capillary blood samples were col-
lected at 15-min intervals in the first hour and at 30-min intervals over the second hour to determine glucose and 
plasma insulin levels. Data analysis was conducted using a paired samples T test or a Wilcoxon signed rank test.
Results: The addition of mulberry leaf extract to sucrose resulted in a significantly lower glycaemic response and 
insulinaemic response compared to a matched placebo (sucrose alone). The change in blood glucose measurements 
were significantly lower at 15 min (p < 0.001), 30 min (p < 0.001), 45 min (p = 0.008), and 120 min (p < 0.001)  and 
plasma insulin measurements were significantly lower at 15 min (p < 0.001), 30 min (p < 0.001), 45 min (p < 0.001), 60 
min (p = 0.001) and 120 min (p < 0.001). The glucose iAUC (− 42%, p = 0.001), insulin iAUC (− 40%, p < 0.001), peak 
glucose (− 40.0%, p < 0.001) and peak insulin (− 41%, p < 0.001) from baseline were significantly lower for white 
mulberry leaf extract compared with the placebo. White mulberry leaf extract was well tolerated and there were no 
reported adverse events.
Conclusions: Mulberry leaf extract can be used as part of lifestyle changes that may lead to healthy blood glucose 
levels.
Trial registration: ISRCTN99601810 (23 October 2020, retrospectively registered)
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Background
Non-communicable diseases (NCDs) account for more 
than 70% of global deaths, with cardiovascular disease, 
cancer, chronic respiratory diseases and type-2 diabetes 
being the most prevalent conditions [1]. NCDs are often 
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preventable through behavioural changes that reduce 
risk factors such as low levels of physical exercise, con-
sumption of an unhealthy diet and the use harmful sub-
stances such as alcohol and tobacco [2]. Controlling and 
preventing NCDs is of increasing importance as the 
interaction between coronavirus disease 2019 (COVID-
19) and NCDs may exacerbate the burden of disease on 
healthcare systems. COVID-19 is associated with car-
diovascular diseases and with ageing populations around 
the world, with many individuals who may have multiple 
chronic co-morbidities, there exists the scenario where 
there are exponential increases in hospitalizations due 
to complications between COVID-19 and pre-existing 
NCDs [3].
One of the predominant NCDs is type-2 diabetes mel-
litus (T2DM). Globally, the number of people with dia-
betes mellitus has quadrupled in the past three decades, 
with more than 90% of those cases being T2DM [4]. The 
International Diabetes Federation estimates that there 
are 463 million adults with diabetes [5] with estimates 
that an additional 7.3% of the world’s adult population 
being considered as prediabetic with either impaired 
fasting glucose (IFG) or impaired glucose tolerance (IGT) 
[6]. Although there are elements of genetic predisposi-
tion to T2DM, an unhealthy diet and sedentary lifestyle 
are contributing drivers of the disease [7]. Many cases of 
T2DM could however be prevented with lifestyle changes 
[4]. The Diabetes Prevention Program (DPP) demon-
strated that lifestyle modification led to a 58% reduction 
in diabetes in at risk groups that had IGT [8] and the ten-
year follow-up of the DPP study showed that the preven-
tion or delay of T2DM can persist for at least ten years 
with lifestyle intervention [9].
Dietary supplements are often used to support life-
style changes. Morus alba L. (common name white mul-
berry) is a small deciduous tree belonging to the Moreae 
tribe of the Moraceae (common name mulberry) family 
of flowering plants and extracts of M. alba have a long 
history of use as traditional medicines [10–12]. M. alba 
leaves are rich in carbohydrates and protein, as well as 
many vitamins and minerals such as beta-carotene, iron, 
calcium, and zinc. They also possess various polyhydroxy 
alkaloids, stilbenoids (such as resveratrol and oxyresvera-
trol), flavonoids (including quercetin and kaempferol), 
and anthocyanins [13, 14]. The polyhydroxylated alka-
loids found in M. alba. belong to the chemical class called 
iminosugars or azasugars and are one of the characteris-
tic identifying compounds found in Morus spp. The most 
predominate iminosugar in M. alba is the piperidine 
iminosugar 1-deoxynojirimycin (DNJ), a D-glucose ana-
logue with a nitrogen group replacing the oxygen on the 
pyranose ring [15]. Due to their structural similarity with 
carbohydrate monosaccharides, iminosugars such as DNJ 
are able to competitively inhibit carbohydrate-digesting 
enzymes such as α-glycosidase and amylase [16].
There are a number of published studies showing the 
beneficial effects of M. alba on blood glucose and a 
recent meta-analysis found that M. alba leaf extracts sig-
nificantly reduced postprandial glucose (PPG) and that 
its use was safe and well tolerated [17].  Reducose® is a 
proprietary food ingredient, made from a water extract 
of M. alba leaves, and can be use in dietary supplements 
or directly blended into functional foods and drinks. A 
previous randomised, placebo-controlled dose-ranging 
study showed that it significantly lowers the PPG and 
postprandial plasma insulin following a starch challenge 
[18]. As different carbohydrates have different glycosidic 
bonds linking their constituent monomers together, with 
different digestive enzymes responsible for their hydroly-
sis, the aim of this study was to conduct a placebo con-
trolled clinical trial using sucrose (α-1,2 glycosidic bond) 
rather than starch (α-1,4 glycosidic bond), which was 
used previously. The previous study tested the benefits 
of Reducose mulberry leaf extract in dietary supplement 
form, administered in capsules. Reducose can also be 
used as an ingredient for functional foods and bever-
ages, and so this study explored the effect of  Reducose® 
when incorporated directly into a beverage containing 
a high amount of sugar. The previous study showed that 
the bioavailability of Reducose is important for efficacy, 
an observation this study sought to confirm by evaluat-
ing the effects of Reducose when it is immediately bio-
available in a liquid solution, rather than being taken in 
the form of a capsule or tablet, which has to dissolve to 
become bioavailable.
In light of the above, the primary objective of this study 
was to determine the effect of a single dose of  Reducose® 
mulberry-extract  (Reducose®) versus placebo on blood 
glucose and insulin responses when co-administered 
in a water solution containing 75  g sucrose in normo-
glycaemic adults. The secondary aim was to show that 
 Reducose® when co-administered with oral sucrose will 
not disproportionately increase the incremental area 
under the curve for plasma insulin concentration over 




A double-blind, randomised, repeat measure, crossover 
design trial was used to study the glycaemic response 
(GR) and insulinaemic response (IR) to a proprietary 
mulberry leaf extract  (Reducose®) compared with a pla-
cebo. Participants acted as their own controls. The trial 
was conducted by the Oxford Brookes Centre for Nutri-
tion and Health at Oxford Brookes University. Ethical 
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approval for the study was obtained from the University 
Research Ethics Committee (UREC) at Oxford Brookes 
University (UREC Registration No: 140806 for glycaemic 
response and UREC Registration No: 110594 for insuli-
naemic response). Participants were given full details 
of the study protocol and the opportunity to ask ques-
tions before giving written informed consent prior to 
participation.
Participants
Thirty-eight healthy men and women participated in the 
study (Table 1) and were recruited from Oxford Brookes 
University, Oxford, UK and from the local community 
between April 2016 and August 2016.
Participants were included in the study if they were: [1] 
aged between 18–60 years, [2] had a BMI between 20 and 
29.9  kg/m2, [3] had fasting blood glucose < 6.1  mmol/l. 
Participants were excluded from the study if they: [1] 
were women who were pregnant or lactating; [2] had 
any known food allergies or intolerance to mulberry leaf 
extracts; [3] had a pre-existing medical condition or tak-
ing medication known to affect glucose regulation and/
or influence digestion and absorption of nutrients; [4] 
had a history of diabetes mellitus (type I/II) or they used 
antihyperglycaemic drugs or insulin to treat diabetes or 
related conditions; [5] used steroids, protease inhibitors 
or antipsychotics medicines as these drugs are known to 
impact glucose metabolism and body fat distribution.
For all participants, anthropometric measurements 
were made in the fasted state during the first session. 
Height was recorded to the nearest centimetre using a 
stadiometer (Seca Ltd, UK), with participants standing 
erect and without shoes. Body weight was recorded to 
the nearest 0.1 kg, with participants wearing light cloth-
ing and no shoes. Body fat percentage was measured 
using a body composition analyser (Tanita BC-418 MA; 
Tanita UK Ltd).
Randomisation
Researchers recruiting the participants were unaware 
of the allocation sequence (concealed allocation). Par-
ticipants were assigned to a participant number accord-
ing to their chronological order of enrolment in the 
study. The allocated participant number was used to 
identify the participants and their corresponding inter-
vention sequence.
The reference product and test products were admin-
istered to participants in a randomised, repeated meas-
ures design. In each participant, the reference product 
and test products were tested on separate days, with at 
least a two-day gap between measurements to minimise 
carry over effects.
Test product
Reducose® mulberry leaf extract (batch num-
ber IM150525) was manufactured for the Spon-
sor (Phynova Group Ltd, Long Hanborough, UK) by 
Purapharm Pharmaceuticals Co. Ltd (Nanning, China). 
 Reducose® is a commercially available aqueous extract 
of the leaves of Morus alba Linn., standardised to con-
tain 4.5– 5.5% DNJ, as determined by high performance 
liquid chromatography. The raw mulberry leaf material 
was analysed for DNJ content, heavy metals, pesticide 
residues, yeast and molds and was then air-dried by 
the raw material supplier. The dried mulberry leaf then 
underwent aqueous extraction and ion exchange chro-
matography to enrich the alkaloid components. The 
eluent was reduced under vacuum and passed through 
ultrafiltration filters prior to spray drying. Maltodextrin 
was added as an excipient to aid spray drying and to 
standardise the extract to contain 5% DNJ.
The test and placebo products were manufactured 
by Chrysalis Health and Beauty Ltd (Nottingham, Eng-
land). The test and placebo products were placed into 
500 mL brown bottles and sealed with screw down caps 
with tamper-evident seals. The test product contained 
75 g sucrose co-blended with 250 mg  Reducose® mul-
berry leaf extract. The placebo product contained 75 g 
sucrose alone. On the day of testing, 250 mL water was 
added to the 500 mL brown bottles and mixed through 
vigorous shaking. The Sponsor provided the treatments 
and bottled water. Both treatments were the same in 
terms of taste, appearance and odour. All products 
were stored in the test kitchen at the Oxford Brookes 
Centre for Nutrition and Health where the temperature 
was monitored and recorded daily.
Table 1 Physical characteristics of study population with 
complete GR and IR data (n = 36)
Values are mean ± SD
BMI body mass index
Variable Mean ± SD
Age (year) 31.8 ± 10.6
Height (m) 1.69 ± 0.08
Weight (kg) 66.9 ± 10.1
BMI (kg/m2) 23.3 ± 2.3
Fat mass (%) 23.5 ± 8.9
Lean body mass (kg) 51.3 ± 9.9
Waist circumference (cm) 80.6 ± 7.3
Hip circumference (cm) 100.2 ± 6.1
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The study products were blinded to both investigator 
and participants.
Sample size
A previous study [18] in 37 healthy individuals using 
250 mg  Reducose® or matched placebo showed a differ-
ence in mean incremental area under the curve (iAUC) 
of 43.1 mmol/l/min between treatment groups. Based on 
a standard deviation of 53.02 mmol/l/min, a sample size 
of 34 participants would provide 90% power to detect a 
similar treatment effect at a two-sided 0.05 significance 
level. In order to account for the potential loss to follow 
up and the possibility that the effect size may differ based 
on using sucrose rather than maltodextrin as the carbo-
hydrate challenge, we aimed to recruit 40 participants to 
complete at least 36 participants.
Experimental protocol
The protocol used was an adaptation from that described 
by Brouns et  al.[19] and was carried out in accordance 
with ISO standards [20]. On the day prior to a test, par-
ticipants were asked to restrict their intake of alcohol and 
caffeine-containing drinks and to restrict their participa-
tion in intense physical activity (for example, long periods 
at the gym, excessive swimming, running, aerobics). Par-
ticipants were also told not to eat or drink after 9.00 pm 
the night before a test, although water was allowed in 
moderation.
At the start of the test period, participants consumed 
the products at a comfortable pace, within 5  min and 
the reference product and test products were served dis-
solved in 250 mL water. Participants remained sedentary 
during each test session and did not consume any addi-
tional food or fluid.
Blood samples were taken at − 5 min and 0 min before 
consumption of the treatments and the baseline value 
taken as a mean of these two values. The products were 
consumed immediately after this and further blood sam-
ples were taken at 15, 30, 45, 60, 90 and 120  min after 
starting to drink the test/reference product. Blood was 
obtained by finger-prick using the  Unistik®3 single-
use lancing device (Owen Mumford). Fingers were not 
squeezed to extract blood from the fingertip as this may 
dilute with plasma. Blood glucose was measured using 
the HemoCue Glucose 201 + analyser  (HemoCue® Ltd), 
which is a photometric enzyme coupled assay system. 
The glucose analyser was calibrated daily using con-
trol solution from the manufacturer. Plasma insulin was 
measured from 300 μL of capillary blood (from finger 
pricks). Blood was collected into chilled  microvette® cap-
illary blood collection tubes treated with dipotassium 
EDTA (CB 300 K2E; Sarstedt Ltd). The  microvette® tubes 
were centrifuged and 200 μL of the supernatant plasma 
obtained. Insulin concentrations in the plasma samples 
were determined by electrochemiluminescence immuno-
assay using an automated analyzer  (Cobas® E411; Roche 
diagnostics).
Statistical analysis
Data were analysed using IBM Statistical Package for 
the Social Sciences (SPSS) version 22.0 (SPSS Inc., Chi-
cago, Illinois). Data are presented as mean, standard 
deviation (SD) and standard error of the mean (SEM) 
values. The blood glucose and plasma insulin iAUC for 
both  Reducose® and the placebo were calculated geo-
metrically by applying the trapezoid rule, according to 
the ISO standards[20]. The peak glucose, peak insulin, 
time of peak glucose and time of peak insulin were cal-
culated as the average of the peak values for the group of 
participants after consuming the placebo and test prod-
ucts. Prior to statistical analysis, the normality of the data 
was tested using the Shapiro-Wilks statistic. The paired-
sample t-test (for normally distributed data) and non-
parametric Wilcoxon signed-rank test (where data were 
not normally distributed) were used to compare blood 
glucose and insulin concentrations, peak blood glucose 
and insulin values, time of the blood glucose and insulin 
peaks and blood glucose and insulin iAUC (over 60, 90 
and 120 min) between  Reducose® and the placebo. Statis-
tical significance was set at p < 0.05.
Results
Thirty-eight healthy participants were recruited (16 male, 
22 female; aged 20 to 58  years). Thirty-seven partici-
pants completed the study. One participant was unable 
to complete the study within the allocated timeframe and 
was withdrawn from the study. For one participant, data 
were missing for plasma insulin and therefore excluded 
from the analysis. Thus, the glycaemic and insulinaemic 
response data are reported for 36 participants. The physi-
cal characteristics of the study population with complete 
GR and IR data are presented in Table 1.
Glycaemic and insulaemic response
There was a significant difference (p < 0.05) in the change 
in blood glucose measurements between  Reducose® and 
the placebo at 15, 30, 45 and 120 min; however, there was 
no significant difference (p > 0.05) in the change in blood 
glucose measurements between  Reducose® and the pla-
cebo at baseline, 60 and 90 min (Fig. 1a). After consum-
ing the placebo, the blood glucose at 120  min dropped 
below the baseline whereas Reducose sustained the blood 
glucose just above the baseline at the end of two hours. 
 Reducose® significantly lowered the peak blood glucose 
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compared with the placebo, however the time of the 
blood glucose peak was not significant (Table  2). There 
was a significant difference between the mean glucose 
iAUC at 60, 90 and 120 min between Reducose and the 
placebo ranging from 42 to 45% (Table 3).
There was a significant difference (p < 0.05) in the 
change in insulin measurements between  Reducose® and 
the placebo at 15, 30, 45, 60 and 120 min; however, there 
was no significant difference (p > 0.05) in the change in 
insulin measurements between  Reducose® and the pla-
cebo at baseline and at 90 min (Fig. 1b). The insulin meas-
urement dropped towards the baseline at 120  min after 
the placebo. After Reducose, the insulin measurement 

































































Fig. 1 a Glucose iAUC for  Reducose® and the placebo. b Insulin iAUC for  Reducose® and the placebo. Values are the mean for 36 participants with 
SEM asterisks show statistical significance (P < 0.05)
Table 2 Peak blood glucose, time of the blood glucose peak, peak insulin and time of the insulin peak (n = 36)
a Statistically significant difference (P < 0.05). Values are Mean (± SD)
b Based on incremental changes that have been adjusted to baseline values
Placebo Reducose® p value Change 
compared to 
Placebo (%)
Peak blood glucose (mmol/l) 7.2 ± 0.7 6.2 ± 0.7  < 0.001a −  40b
Time of blood glucose peak (min) 27.5 ± 9.1 31.3 ± 7.5 0.050  + 12
Peak insulin (μU/ml) 62.77 ± 29.87 37.27 ± 22.58  < 0.001a −  41b
Time of the insulin peak (min) 31.7 ± 14.7 40.8 ± 22.6 0.149  + 22
Table 3 Mean (± SD) glucose iAUC and insulin iAUC at 60, 90 and 120 min (n 36)
a Statistically significant difference (p < 0.05). Values are Mean (± SD)
Placebo Reducose® p value Change 
compared to 
Placebo (%)
Glucose iAUC 60 88.6 ± 35.4 48.9 ± 23.0  < 0.001a − 45
Glucose iAUC 90 104.3 ± 51.4 58.7 ± 32.7  < 0.001a − 44
Glucose iAUC 120 110.2 ± 63.9 64.0 ± 37.4 0.001a − 42
Insulin iAUC 60 2094.64 ± 1003.13 1060.07 ± 618.91  < 0.001a − 49
Insulin iAUC 90 2691.44 ± 1372.52 1457.22 ± 822.51  < 0.001a − 46
Insulin iAUC 120 2915.94 ± 1642.54 1752.24 ± 1013.20  < 0.001a − 40
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significantly lowered the peak plasma insulin levels com-
pared with placebo, however the time to the peak was not 
significantly different (Table  2). There was a significant 
difference (p < 0.05) in the plasma insulin iAUC between 
 Reducose® and the placebo at 60, 90 and 120 min ranging 
from 40 to 49% (Table 3).
The results demonstrated that blending Reducose 
directly into the test meal positively impact efficacy with 
the reduction in peak postprandial glucose being 42% 
lower (p < 0.001) and postprandial plasma insulin being 
41% lower (p < 0.001) than the placebo arm. There were 
no serious adverse events or adverse events during this 
study.
Discussion
Previous research [17, 18] has demonstrated that white 
mulberry extracts can lower postprandial glucose and 
insulin levels following ingestion of long-chain carbo-
hydrates, such as maltodextrin. Carbohydrates such 
as maltodextrin are glucose polymers, with each glu-
cose unit joined to the next one in the chain through an 
α-1,4-glycosidic bond. These carbohydrates are digested 
by enzymes such as amylase and α-glucosidase. Sucrose 
however is a disaccharide made up of one molecule 
of glucose that is bonded through an α-1,2-glycosidic 
bond to one molecule of fructose. Due to the different 
bond orientation, sucrose is not digested by amylase or 
α-glucosidase but is rather broken down to its basic mon-
osaccharides through the actions of the enzyme sucrase 
or sucrase-isomaltase [21].
In this randomised, double blind, placebo-controlled 
clinical trial,  Reducose® mulberry leaf extract signifi-
cantly lowered postprandial increases in blood glucose 
and plasma insulin in normoglycaemic individuals fol-
lowing the ingestion of sucrose. The results showed a 
clear and significant effect of white mulberry leaf extract 
to decrease both glucose and insulin concentrations fol-
lowing a sucrose challenge. The study showed that both 
the peak blood glucose and blood insulin levels were low-
ered, as was the total postprandial glucose and insulin 
levels, as represented by iAUC.
The mulberry leaf extract group exhibited a more bal-
anced glucose response, with the participant’s blood glu-
cose levels never dropping below the fasted level, whilst 
the placebo group showed a significantly lower blood 
glucose level at the 120-min time point (p < 0.001), lev-
els lower than the fasted baseline. This transient reactive 
hypoglycaemia in the placebo group may be attributed to 
the rapid increase in blood glucose and the consequent 
spike in plasma insulin. In non-diabetic subjects, incre-
tins are responsible for 50–70% of total insulin secretion. 
Glucose-dependent insulinotropic peptide (GIP) and 
glucogon-like peptide-1 (GLP-1) both play an important 
role in glucose homeostasis[22], but the rate of release 
of these incretins differs depending on the stimulatory 
nutrient. GIP is synthesized by K-cells in the duodenum 
and jejenum and is very sensitive to glucose stimulation 
but has lower sensitivity to disaccharides and polysac-
charides. GLP-1, which is produced by the L-cells that 
predominate at the distal end of the small intestine in the 
ileum, shows similar stimulatory sensitivity to glucose as 
to disaccharides and polysaccharides[23]. In healthy sub-
jects, GIP is responsible for the majority of postprandial 
incretin-mediated insulin response[22] and in situations 
with lower amounts of free glucose, there would be a cor-
responding lower GIP-mediated insulin response. This 
may explain the differences in blood glucose responses 
between the test groups in the current study and is in 
line with the established inhibitory effect that mulberry 
leaf extract has on glucosidase enzymes in the brush 
border[24]. In the placebo group, the sucrose test drink 
would be rapidly hydrolysed to glucose and fructose by 
glycosidase enzymes in the brush border of the intestine, 
resulting in a higher insulin release due to stimulation 
by both GIP and GLP-1, whilst in the  Reducose® group, 
lower levels of free glucose would be available due to the 
inhibition of the hydrolysing enzymes, resulting in lower 
GIP levels. Early postprandial reactive hypoglycaemia, 
which occurs within 1–2 h of eating, can be caused by an 
exaggerated incretin effect as excessive amounts of GIP 
and GLP-1 are released through the sudden glucose load-
ing, stimulating insulin exocytosis and upregulation of 
GLUT-4 channels, which results in a rapid lowering of 
blood glucose levels[25].
This study also found that the mulberry leaf extract 
group also had significantly higher insulin levels at 
120  min (p < 0.001). This finding may again be attribut-
able to an incretin effect and reflect the malsorption 
of the sucrose test meal. The majority of carbohydrate 
digestion takes place in the duodenum and early parts 
of the jejenum, where there is a higher concentration of 
glucosidase enzymes in the brush border, with the more 
distally situated jejenum and ileum being sites of nutrient 
absorption[25]. There is consequently limited scope for 
digestion and absorption of disaccharides and polysac-
charides that have escaped break-down in the proximal 
small intestine, as only monosaccharides can be absorbed 
into the body. These undigested nutrients may however 
stimulate the L-cells in the ileum resulting in secretion of 
GLP-1. GLP-1 has number of physiological actions, one 
of which is glucose stimulated insulin release, and the 
rise in insulin levels that are observed in the mulberry 
leaf extract treatment arm after 90-min may be attributed 
to the stimulation of GLP-1 due to sucrose malsorption. 
This supposition is supported by literature as reported 
small bowel transit times correlate with the rise in insulin 
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after 90 min[26] and treatment with α-glucosidase inhibi-
tors such as acarbose are associated with increased post-
prandial GLP-1 levels[27].
White mulberry leaf extract has broad applications in 
blunting the blood glucose responses of foods that con-
tain a range of dietary carbohydrates, with the results 
from this study showing that mulberry leaf extract is 
effective in lowering postprandial glucose rises after con-
suming α-1,2 bonded carbohydrates in addition to being 
effective in response to α-1,4 bonded carbohydrates as 
demonstrated previously[18]. In comparison other func-
tional ingredients that impact the digestion of carbo-
hydrates, such as white kidney bean extract (reported 
efficacious dose ranges from 750  mg-3000  mg), only 
inhibit α-amylase enzymes (hydrolyse α-1,4 bonded poly-
saccharides into oligo- and disaccharides) and therefore 
would not prevent the breakdown of sucrose into its car-
bohydrate monomers[28].
The findings of this study agree with previous research 
that has demonstrated the sucrase inhibitory effect of 
white mulberry leaf extracts in healthy and type-2 dia-
betic participants[29, 30]. However, the ratio of mul-
berry leaf extract to sucrose was higher (3 g mulberry leaf 
extract with 30 g sucrose; 1 g mulberry leaf extract with 
75 g sucrose) in those studies[29, 30] compared  with the 
current study where the dose of   Reducose® mulberry 
leaf extract was  lower  due to greater  levels of purifica-
tion  (250  mg  mulberry leaf extract  with75  g  sucrose). 
Similar to Mudra et  al. [29], the use of pure sucrose as 
a  test food in this study averted any interfering effects 
from other ingredients in the Japanese confections used 
by Nakamura et  al. [30]. Furthermore, another strength 
of this study is the larger sample size compared to previ-
ous studies investigating the effect mulberry leaf extracts 
on sucrose digestion and absorption [29, 30].
Previous research by this research group [18] reported 
that the choice of dosage format could impact the efficacy 
of mulberry leaf extracts. In  the previous study, the test 
product did not have a notable effect in lowering glucose 
or insulin responses until 45 min after ingestion and con-
sequently the peak glucose and insulin levels were not 
decreased to the anticipated level as peak levels occurred 
at 30 min. It was hypothesized that the capsule material 
selected for use in the study (hydroxypropyl methylcellu-
lose), which in this case had a 15-min disintegration time, 
impaired the bioavailability of the mulberry leaf extract 
as blood glucose in the test participants had already 
started to peak before mulberry leaf extract was bioavail-
able to inhibit the glycosidase enzymes. To explore this 
hypothesis further, in the current study, the mulberry leaf 
extract was blended directly into the carbohydrate chal-
lenge and dissolved in water so that it would be immedi-
ately bioavailable. The results demonstrated that blending 
mulberry leaf extract directly into the test meal positively 
impacts efficacy with the reduction in peak postprandial 
glucose being 42% lower and postprandial plasma insu-
lin being 41% lower than the placebo arm, compared 
with a non-significant, 3% reduction reported in Lown 
et al. [18]. This suggests that in order to get the best effect 
from mulberry leaf extract, a suitable intake form such as 
liquids, fast-dissolving tablets or capsules, or chewable 
dosage forms should be considered during the product 
development when mulberry leaf extract is used as a key 
ingredient.
The findings of the current study show that mulberry 
leaf extract could be beneficial for people who are try-
ing to control their blood glucose response to foods. As 
noted previously, the DPP study reported that lifestyle 
changes had the greatest impact in preventing diabetes in 
participants that had IGT [8, 9] and preventing the devel-
opment of latent or overt T2DM is of growing impor-
tance considering the increased risk factors associated 
with COVID-19 [3]. Changing health-related behaviour 
is however difficult as there are both social and psy-
chological factors that need to be modified before such 
changes can be made [31]. Eating and physical activity 
are processes and practices that are embedded in social 
life and individual habits in eating and exercising are 
ingrained in an individual’s routine. Whilst most peo-
ple are rational, that does not always equate to rational 
behaviour. Most smokers want to stop smoking and most 
overweight people want to lose weight, but the majority 
of smokers do not stop and most diets fail because knowl-
edge and rational assessment does not drive behavioural 
change, as behaviour is largely automatic and usually 
unaccompanied by conscious reflection [31, 32]. Small, 
incremental changes or nudges are more likely to result 
in health behaviour changes [32, 33]. For people who are 
concerned about their blood glucose levels, using dietary 
supplements such as mulberry leaf extract to blunt the 
glycaemic and insulinaemic responses to food could be 
considered such a small incremental change or nudge.
Limitations
This study only evaluated the short-term effects of mul-
berry leaf extract using a single dose and therefore did 
not capture any benefits or potential side effects that 
could occur with long-term administration. We also 
used a simple carbohydrate in fasting individuals and 
did not evaluate the pragmatic effects of mulberry leaf 
extract when carbohydrates are mixed with fats and 
proteins in the diet as proteins and fats may impact 
carbohydrate digestion and the rate of gastric empty-
ing. Whilst a study in a complex meal helps to estab-
lish real-world benefits (this is currently being explored 
in an ongoing clinical study), understanding the effects 
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of  Reducose® on the different types of carbohydrates is 
nonetheless important due to the variety of carbohy-
drates in the human diet, each of which contributes to 
the glycaemic response but require different enzymes 
for digestion. As this study was conducted in normogly-
caemic participants, care should be taken when extrap-
olating the results to participants with dysglycaemia.
Conclusions
We have demonstrated that  Reducose® mulberry leaf 
extract significantly lowers the increase in plasma glu-
cose after ingestion of sucrose over 120  min. Total 
insulin rises were also significantly suppressed over the 
same period. None of the participants reported any side 
effects and no adverse events were recorded during the 
study. This study builds on the body of evidence that 
supports the use of mulberry lead extracts as a part of 
lifestyle changes that may lead to healthy blood glucose 
levels.
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